Evaluation of Neuroprotective Effect of Thymoquinone Nanoformulation in the Rodent Cerebral Ischemia-Reperfusion Model

Table 4

Brain and plasma pharmacokinetic parameters of thymoquinone loaded PLGA nanoparticles after intravenous and intranasal delivery.

Formulation	Organ/tissue	Peak; plasma conc.; (ng/mL)	Time peak; plasma conc.; (h)	Half-life; (h)	Rate of elimination; (h^−1)	(ng mL^−1 h)	(ng mL^−1 h)
TQ-PLGA NPs (i.v.)	Brain	390.61 ± 54.44	8	18.11 ± 1.97	0.010 ± 0.003	11204.3 ± 3211.6	20296.3 ± 3265.6
	Plasma	15897.67 ± 3443.52	—	62.34 ± 7.04	0.038 ± 0.004	312654.2 ± 6542.6	351453.2 ± 14915.1
TQ-PLGA NPs (i.n.)	Brain	996.43 ± 119.36	12	118.23 ± 3.97	0.005 ± 0.000	33771.2 ± 994.5	98675.6 ± 8157.1
	Plasma	3465.33 ± 664.16	4	194.24 ± 9.87	0.003 ± 0.000	142315.1 ± 33217.3	359773.4 ± 44132.3

; data represent mean ± SEM.